[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C: Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol; 2005 Dec 7;11(45):7118-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.
  • AIM: To assess the value of long-chain omega-3 fatty acids (FAs) supplementation in addition to amino-salicylic-acid (5-ASA) in pediatric patients with Crohn's disease (CD).
  • METHODS: Thirty-eight patients (20 males and 18 females, mean age 10.13 years, range 5-16 years) with CD in remission were randomized into two groups and treated for 12 mo.
  • CONCLUSION: Enteric-coated omega-3 FAs in addition to treatment with 5-ASA are effective in maintaining remission of pediatric CD.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. MESALAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437657.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Fatty Acids, Omega-3; 4Q81I59GXC / Mesalamine
  • [Other-IDs] NLM/ PMC4725070
  •  go-up   go-down


2. Tao R, Emslie G, Mayes T, Nakonezny P, Kennard B, Hughes C: Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry; 2009 Jan;48(1):71-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
  • OBJECTIVE: : Less than half of youths achieve remission (minimal to no symptoms) after acute antidepressant treatment.
  • Early identification of who will or will not respond to treatment and achieve remission may help clinicians formulate treatment decisions and shorten the time spent on ineffective treatments.
  • In a prospective open-label fluoxetine study, we investigate indicators of acute treatment response and remission.
  • The rate of symptom improvement, however, is a good indicator of acute treatment response.
  • A significant symptom reduction (approximately 50%) by week 4 is needed to achieve remission at the end of acute treatment.
  • CONCLUSIONS: : This study demonstrated that the rate of symptom improvement during early weeks of acute fluoxetine treatment is a good indicator of remission.
  • Treatment approach may be reevaluated and modified as early as week 4 during acute treatment.Clinical trials registration information-Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents.
  • [MeSH-minor] Acute Disease. Adolescent. Child. Female. Humans. Male. Outcome Assessment (Health Care) / statistics & numerical data. Personality Assessment / statistics & numerical data. Prognosis. Psychometrics / statistics & numerical data. ROC Curve. Secondary Prevention. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Major depressive disorder.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Gen Psychiatry. 2000 Jan;57(1):29-36 [10632230.001]
  • [Cites] Psychiatry Res. 1999 Oct 11;91(3):127-39 [10641577.001]
  • [Cites] Clin Ther. 2003 Aug;25(8):2289-304 [14512135.001]
  • [Cites] JAMA. 2004 Aug 18;292(7):807-20 [15315995.001]
  • [Cites] Arch Gen Psychiatry. 1983 Nov;40(11):1228-31 [6639293.001]
  • [Cites] Gen Hosp Psychiatry. 1992 Jul;14(4):230-6 [1505744.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):471-81 [9276848.001]
  • [Cites] Biometrics. 1997 Sep;53(3):983-97 [9333350.001]
  • [Cites] Mol Psychiatry. 1998 Nov;3(6):508-11 [9857976.001]
  • [Cites] J Affect Disord. 1999 Aug;54(3):269-76 [10467970.001]
  • [Cites] J Child Psychol Psychiatry. 2005 Jul;46(7):735-54 [15972068.001]
  • [Cites] J Nerv Ment Dis. 2006 Apr;194(4):241-8 [16614544.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1841-53 [16794566.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1427-39 [17135988.001]
  • [Cites] Psychiatry Res. 2007 Jan 15;149(1-3):195-200 [17157390.001]
  • [Cites] CNS Spectr. 2007 Feb;12(2):147-54 [17277715.001]
  • [Cites] JAMA. 2007 Apr 18;297(15):1683-96 [17440145.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):667-86 [17513980.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Nov;22(11):1141-6 [17486678.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1503-26 [18049300.001]
  • [Cites] Am J Psychiatry. 2008 Apr;165(4):459-67 [18281410.001]
  • [Cites] Biol Psychiatry. 2008 Jun 15;63(12):1171-7 [18061147.001]
  • [Cites] Arch Gen Psychiatry. 1986 May;43(5):421-9 [3964020.001]
  • (PMID = 19057412.001).
  • [ISSN] 1527-5418
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00332787
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH039188; United States / NIMH NIH HHS / MH / R01 MH039188-13; United States / NIMH NIH HHS / MH / R01 MH39188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 01K63SUP8D / Fluoxetine
  • [Other-IDs] NLM/ NIHMS173252; NLM/ PMC2822388
  •  go-up   go-down


3. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H, Pediatric Oncology Group: Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood; 2006 Feb 15;107(4):1315-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
  • Relapse is a major obstacle in the cure of acute myeloid leukemia (AML).
  • The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS).
  • Of the 282 children randomly assigned to receive standard DAT induction, 248 (87.9%) achieved remission compared to 253 (91%) of the 278 receiving high-dose DAT (P = ns).
  • Children with HLA-identical sibling donors who achieved a complete remission received an allogeneic bone marrow transplant as consolidation.
  • Of the 418 children who achieved remission and went on to consolidation with and without CsA, the DFS was 40.6% and 33.9%, respectively (P = .24).
  • Overexpression of P-gp was infrequent (14%) in this pediatric population.
  • In this study, intensifying induction with high-dose DAT and the addition of CsA to consolidation chemotherapy did not prolong the durations of remission or improve overall survival for children with AML.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1867-75 [10784627.001]
  • [Cites] Blood. 2000 Jul 1;96(1):365-8 [10891476.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Curr Oncol Rep. 2000 Nov;2(6):529-38 [11122889.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):211-33 [11355932.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):95-118 [11355926.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3605-11 [11369657.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5461-7 [11454692.001]
  • [Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Leukemia. 2002 May;16(5):833-9 [11986944.001]
  • [Cites] Leukemia. 2002 May;16(5):920-7 [11986955.001]
  • [Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]
  • [Cites] Blood. 1980 Jun;55(6):960-8 [6966518.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4665-70 [1873811.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1492-7 [7916390.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Apr;9(2):363-82 [7642468.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2329-42 [7545025.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2042-8 [8609715.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4809-16 [8639853.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3010-20 [8674056.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):315-27 [9517503.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1046-56 [10419897.001]
  • [CommentIn] Blood. 2006 Jun 15;107(12):4975-6; author reply 4976-7 [16754781.001]
  • (PMID = 16254147.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90916
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / P-Glycoprotein; 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; LJ2P1SIK8Y / Mitolactol
  • [Other-IDs] NLM/ PMC1895393
  •  go-up   go-down


Advertisement
4. Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, Turck D, Schmitz J, Maurage C, Girardet JP, Belli D, Lamireau T, Sarles J, Chouraqui JP, Descos B, Dabadi A, Meyer M, Olives JP, Mary JY: Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol; 2009 Jan;33(1 Pt 1):31-40
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
  • AIM: This study aimed to test the efficacy of mesalazine in maintaining remission in pediatric Crohn's disease (CD) following successful flare-up treatment.
  • CONCLUSION: Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118966.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 4Q81I59GXC / Mesalamine
  •  go-up   go-down


5. Saldano DD, Chaviano AH, Maizels M: Sustainability of remission of pediatric primary nocturnal enuresis--comparison of remission using Try for Dry vs. non-Try for Dry treatment plans. Urol Nurs; 2008 Aug;28(4):263-6
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustainability of remission of pediatric primary nocturnal enuresis--comparison of remission using Try for Dry vs. non-Try for Dry treatment plans.
  • This study examined the sustainability of remission of primary nocturnal enuresis (PNE) using an algorithm-based multimodal treatment plan, Try for Dry.
  • Remission of PNE using the Try for Dry treatment method was retained longer and more often than using a non-Try for Dry plan.
  • [MeSH-minor] Adolescent. Antidiuretic Agents / therapeutic use. Child. Combined Modality Therapy. Constipation / etiology. Constipation / prevention & control. Deamino Arginine Vasopressin / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Equipment Failure. Humans. Incidence. Kaplan-Meier Estimate. Mandelic Acids / therapeutic use. Muscarinic Antagonists / therapeutic use. Nursing Evaluation Research. Remission Induction. Retrospective Studies. Surveys and Questionnaires. Toilet Training. Treatment Outcome. Urodynamics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18771159.001).
  • [ISSN] 1053-816X
  • [Journal-full-title] Urologic nursing
  • [ISO-abbreviation] Urol Nurs
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiuretic Agents; 0 / Mandelic Acids; 0 / Muscarinic Antagonists; ENR1LLB0FP / Deamino Arginine Vasopressin; K9P6MC7092 / oxybutynin
  •  go-up   go-down


6. Banerjee S, Rahhal R, Bishop WP: Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr; 2006 Sep;43(3):353-6
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis.
  • To date, no pediatric literature describes long-term AZA monotherapy after induction of remission with corticosteroids.
  • The time to complete biochemical remission on corticosteroids and AZA was 230 days (range, 74-288 days).
  • Long-term remission of AIH was possible in our case series with the early introduction and maintenance treatment with AZA as monotherapy.
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Alanine Transaminase / blood. Antibodies, Antinuclear / blood. Aspartate Aminotransferases / blood. Autoantibodies / blood. Child. Female. Humans. Liver / pathology. Muscle, Smooth / immunology. Prednisone / administration & dosage. Recurrence. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):490 [18030221.001]
  • (PMID = 16954959.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Antinuclear; 0 / Autoantibodies; 0 / Immunosuppressive Agents; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Heuschkel R: Enteral nutrition should be used to induce remission in childhood Crohn's disease. Dig Dis; 2009;27(3):297-305
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteral nutrition should be used to induce remission in childhood Crohn's disease.
  • BACKGROUND: Exclusive enteral nutrition has been used over many years as a therapy to try and achieve a remission in adults and children presenting with acute Crohn's disease.
  • RESULTS: Although the evidence base remains quite limited, further data are available that suggest a clear benefit of exclusive enteral nutrition as an efficacious alternative to steroid therapy at inducing a clinical remission in Crohn's disease.
  • [MeSH-minor] Child. Humans. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19786755.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 81
  •  go-up   go-down


8. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ: A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood; 2010 Sep 30;116(13):2205-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia.
  • Survival of pediatric acute myeloid leukemia (AML) has improved considerably over the past decades.
  • This review summarizes phase 3 clinical trials that compared allo-SCT with chemotherapy (including autologous SCT) in pediatric AML, excluding studies that did not use the intention-to-treat analysis or correct for time-to-transplantation.
  • Because allo-SCT also gives more severe side effects and results more often in secondary malignancies than chemotherapy, we do not recommend allo-SCT in first remission for pediatric AML in general.
  • Further research should focus on the possibility that subgroups might benefit from allo-SCT, aiming at further improvements in the prognosis of pediatric AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials, Phase III as Topic. Cost-Benefit Analysis. Disease-Free Survival. Humans. Remission Induction. Survival Analysis. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome


9. Bader P, Willasch A, Klingebiel T: Monitoring of post-transplant remission of childhood malignancies: is there a standard? Bone Marrow Transplant; 2008 Oct;42 Suppl 2:S31-4
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of post-transplant remission of childhood malignancies: is there a standard?
  • Consecutive post transplant MRD monitoring, together with chimerism analysis, allows the detection of impending relapse in a substantial group of children transplanted for acute leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Graft Rejection / prevention & control. Leukemia / therapy. Monitoring, Physiologic / methods. Monitoring, Physiologic / standards. Peripheral Blood Stem Cell Transplantation. Transplantation Chimera
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Neoplasm, Residual. Recurrence. Risk Factors

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978741.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


10. To T, Gershon A, Wang C, Dell S, Cicutto L: Persistence and remission in childhood asthma: a population-based asthma birth cohort study. Arch Pediatr Adolesc Med; 2007 Dec;161(12):1197-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence and remission in childhood asthma: a population-based asthma birth cohort study.
  • OBJECTIVES: To examine and predict the persistence of childhood asthma.
  • MAIN OUTCOME MEASURES: Those who continued to have asthma events (hospitalization and/or physician visit) between ages 6 and 11 years were considered to have "persistent asthma," while others were in "remission."
  • By age 12 years, nearly half (48.6%) were in remission.
  • CONCLUSION: The concentration of health services use within 1 year following the initial diagnosis of childhood asthma points to the need for attentive follow-up and ongoing management and education strategies in the early years.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056566.001).
  • [ISSN] 1538-3628
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Hafiz MG, Mannan MA: Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its effect on induction of remission. Mymensingh Med J; 2008 Jul;17(2 Suppl):S46-51
MedlinePlus Health Information. consumer health - Malnutrition.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its effect on induction of remission.
  • This prospective study was aimed to evaluate the nutritional status at initial presentation in childhood acute lymphoblastic leukemia (ALL) and to ascertain the effects of nutrition on induction of remission.
  • Then, protocol based induction of remission was started.
  • So, it is concluded that under-nutrition is very usual at initial presentation in childhood ALL, are more prone to suffer from infection and thus prolong the duration of induction, hospital stay, even can lead to death.
  • Optimum nutritional support can play a vital role in the outcome of induction of remission in childhood ALL.


12. Jack F, Hayne H: Childhood amnesia: Empirical evidence for a two-stage phenomenon. Memory; 2010 Nov;18(8):831-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood amnesia: Empirical evidence for a two-stage phenomenon.
  • The term childhood amnesia refers to the inability of adults to remember events from their infancy and early childhood.
  • If we plot the number of memories that adults can recall as a function of age during childhood, the number of memories reported increases gradually as a function of age.
  • Typically, this finding has been used to argue that gradual changes in memory development contribute to a gradual decline in childhood amnesia during the preschool period.
  • Alternatively, it is possible that pooling data across participants has obscured more abrupt, stage-like changes in the remission of childhood amnesia.
  • In the present study we examined the number and distribution of childhood memories for individual participants.
  • Six adults were repeatedly interviewed about their childhood memories.
  • We found that the distribution of adults' early childhood memories may be less continuous than pooled data suggest.
  • This finding has important implications for current explanations of childhood amnesia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924948.001).
  • [ISSN] 1464-0686
  • [Journal-full-title] Memory (Hove, England)
  • [ISO-abbreviation] Memory
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Rosh JR: Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep; 2008 Jun;10(3):302-7
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease.
  • Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn's disease unresponsive to conventional therapy.
  • Additionally, although regularly scheduled administration maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must continue it for maintenance.
  • Finally, the optimal placement of infliximab in the algorithm for the medical treatment of pediatric inflammatory bowel disease remains an open question.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625142.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Glucocorticoids; B72HH48FLU / Infliximab
  • [Number-of-references] 47
  •  go-up   go-down


14. Callenbach PM, van den Boogerd EH, de Coo RF, ten Houten R, Oosterwijk JC, Hageman G, Frants RR, Brouwer OF, van den Maagdenberg AM: Refinement of the chromosome 16 locus for benign familial infantile convulsions. Clin Genet; 2005 Jun;67(6):517-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign familial infantile convulsions (BFIC) is an autosomal dominantly inherited partial epilepsy syndrome of early childhood with remission before the age of 3 years.

  • Genetic Alliance. consumer health - Chromosome 16.
  • Genetics Home Reference. consumer health - familial paroxysmal kinesigenic dyskinesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857419.001).
  • [ISSN] 0009-9163
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


15. Hamrin V, Pachler M: Pediatric bipolar disorder: evidence-based psychopharmacological treatments. J Child Adolesc Psychiatr Nurs; 2007 Feb;20(1):40-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric bipolar disorder: evidence-based psychopharmacological treatments.
  • TOPIC: Pediatric bipolar disorder can cause severe disturbances in global functioning.
  • Diagnosing pediatric bipolar disorder is challenging due to the range of symptom expression, developmental differences as compared to adults, presence of comorbid disorders, and developing diagnostic criteria.
  • PURPOSE: This paper will help child psychiatric nurses have a better understanding of the unique presentation of pediatric bipolar disorder to facilitate selection of appropriate medication treatment options, taking into account symptom presentation, presence of comorbid diagnosis, drug efficacy, adverse effects, and drug-drug interactions based on research findings.
  • SOURCES: Literature specific to assessment and psychopharmacological treatment of pediatric bipolar disorder was reviewed.
  • Psychopharmacological treatment with the use of specific mood stabilizers and/or atypical antipsychotic medications is warranted depending on symptom presentation; however, monotherapy with mood stabilizers has not demonstrated effectiveness in long-term remission of pediatric bipolar symptoms.
  • Recent research indicates that a combined treatment with two mood stabilizers or a mood stabilizer and an antipsychotic holds promising results for pediatric bipolar I, for youth with acute manic symptoms plus psychosis, and for long-term remission of symptoms.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Child Adolesc Psychiatr Nurs. 2008 May;21(2):68 [18429835.001]
  • (PMID = 17284237.001).
  • [ISSN] 1073-6077
  • [Journal-full-title] Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc
  • [ISO-abbreviation] J Child Adolesc Psychiatr Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antidepressive Agents; 0 / Antimanic Agents
  • [Number-of-references] 106
  •  go-up   go-down


16. Kawasaki Y, Suzuki S, Matsumoto A, Takano K, Suyama K, Hashimoto K, Suzuki J, Suzuki H, Hosoya M: Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis. Pediatr Nephrol; 2007 Jun;22(6):889-92
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, there have been reports on the efficacy of low-density lipoprotein (LDL) apheresis (LDL-A) for focal and segmental glomerulosclerosis (FSGS) in pediatric patients.
  • The patient has been in remission from FSGS for 12 years since LDL-A.
  • These findings suggest that LDL-A may be useful in maintaining long-term remission from pediatric FSGS.

  • Genetic Alliance. consumer health - Focal Segmental Glomerulosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277952.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lipoproteins, LDL; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


17. Hara Y, Kamura Y, Oikawa A, Shichino H, Mugishima H, Goto H: [Case of pediatric chronic myeloid leukemia with bilateral visual loss onset]. Nippon Ganka Gakkai Zasshi; 2010 May;114(5):459-63
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of pediatric chronic myeloid leukemia with bilateral visual loss onset].
  • BACKGROUND: Chronic myeloid leukemia (CML) during childhood is rare, and only been a few cases showed visual disturbances as an initial symptom.
  • We report a pediatric CML case diagnosed by bilateral visual loss.
  • CONCLUSION: Recent leukemia therapy including imatinib is effective not only for ocular lesions but also to induce hematological remission in childhood CML.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Vision, Low / etiology. Vision, Low / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / blood. Child. Fusion Proteins, bcr-abl / blood. Humans. Hydroxyurea / therapeutic use. Imatinib Mesylate. Leukapheresis. Male. Philadelphia Chromosome. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545220.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


18. Podracká L, Böör A, Sasinka M: [Cyclosporin A versus cyclophosphamide in the treatment of nephrotic syndrome in children]. Cas Lek Cesk; 2008;147(1):38-43
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclosporin A and cyclophosphamide are widely used; however their relative effectiveness in maintaining remission of childhood nephrotic syndrome remains controversial.
  • In 8 corticoresistant nephrotic syndrome patients (61.5%) from 13 children treated with cyclosporin A no remission occurred, in 5 children (38.5%) was remission obtained within 10 weeks, however in 4 of them relapsed disease during cyclosporin A therapy.
  • 19 (70.4%) of 27 patients on cyclophosphamide therapy were in remission, in 8 of them (42.1%) even 2 years after cyclophosphamide therapy.
  • CONCLUSIONS: Cyclophosphamide therapy of childhood nephrotic syndrome is more effective in maintaining long-term remission than cyclosporin A treatment.
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Male. Remission Induction

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323041.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] slo
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


19. Benmiloud S, Steffens M, Beauloye V, de Wandeleer A, Devogelaer JP, Brichard B, Vermylen C, Maiter D: Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr; 2010;74(4):241-50
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood.
  • BACKGROUND: Little is known regarding long-term bone deficit in relationship with the modalities of cancer therapy among survivors of childhood malignancy.
  • METHODS: Bone mineral density (BMD) was evaluated at lumbar spine (LS), total hip and femoral neck in 89 patients (44 men) more than 5 years after remission of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL).
  • CONCLUSIONS: A low bone mass is frequently observed in adult survivors of childhood ALL and NHL, and is associated with male gender at the LS and with dexamethasone treatment, cranial irradiation and BMT/TBI at the hip.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Density / drug effects. Bone Density / radiation effects. Lymphoma, Non-Hodgkin / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


20. Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE: Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes. J Urol; 2007 Oct;178(4 Pt 2):1758-61; discussion 1762
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes.
  • PURPOSE: We compared the remission of pediatric primary nocturnal enuresis in groups of children who used a physician advised practice plan vs a parent chosen alternative.
  • RESULTS: We found that the probability of remission by the end of the study for the physician advised treatment group was significantly higher than that of the parent choice group (88% vs 29%, Kaplan-Meier curve p <0.0001).
  • CONCLUSIONS: The group of children who followed physician advised treatment for primary nocturnal enuresis showed significantly earlier remission of primary nocturnal enuresis than children who followed the parent choice treatment (25th percentile 2 vs 10 weeks).

  • MedlinePlus Health Information. consumer health - Bedwetting.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707433.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiuretic Agents; 0 / Mandelic Acids; 0 / Parasympatholytics; ENR1LLB0FP / Deamino Arginine Vasopressin; K9P6MC7092 / oxybutynin
  •  go-up   go-down


21. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM: Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol; 2007 Dec;102(12):2804-12; quiz 2803, 2813
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.
  • BACKGROUND: The thiopurines, azathioprine and 6-mercaptopurine, are traditional first-line immunomodulatory agents in adult and pediatric Crohn's disease, but the comparative efficacy and safety of methotrexate have seldom been examined.
  • We report outcomes with methotrexate treatment in pediatric patients previously refractory to or intolerant of thiopurines.
  • METHODS: In a four-center, retrospective cohort study, efficacy of methotrexate in maintaining remission was assessed by PCDAI measurements, steroid use, and height velocity.
  • RESULTS: Forty-two percent of 60 children treated with methotrexate were in clinical remission without steroids at both 6 and 12 months.
  • CONCLUSION: Methotrexate appears effective in maintaining remission in pediatric Crohn's disease, when thiopurines have failed.
  • Consideration should be given to its use earlier in pediatric treatment algorithms.


22. Castro M, Rossi L, Papadatou B, Bracci F, Knafelz D, Ambrosini MI, Calce A, Serafini S, Isacchi G, D'Orio F, Mambrini G, Magnani M: Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr; 2007 Apr;44(4):423-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease.
  • BACKGROUND: Inflammatory bowel disease (IBD) present in childhood in 15% to 25% of cases.
  • The aim of therapy in children is not only to guarantee normal growth but also to prevent relapse and to maintain remission.
  • Steroids are effective to induce remission; however, resistance, dependency, and irreversible side effects can develop.
  • The aim of this study was to determine whether treatment with repeated infusions of autologous red blood cells (RBCs) loaded with dexamethasone 21-phosphate (Dex 21-P) is safe and allows maintenance of long-term remission in children with steroid-dependent Crohn disease (CD).
  • PATIENTS AND METHODS: Eighteen consecutive pediatric patients who met the inclusion criteria were admitted to the study.
  • At the beginning of treatment and after 6, 12, and 24 months, we performed clinical evaluation according to the Pediatric Crohn Disease Activity Index (pCDAI).
  • Endoscopic findings showed remission in 44% of patients.
  • CONCLUSIONS: These data suggest that repeated infusions of RBCs loaded with Dex 21-P can be safe and useful to maintain long-term remission in pediatric patients with moderately active CD.
  • [MeSH-minor] Adolescent. Blood Transfusion, Autologous. Child. Child, Preschool. Female. Humans. Male. Pilot Projects. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414137.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 312-93-6 / dexamethasone 21-phosphate; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


23. Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH: Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis; 2006 Sep;12(9):831-6
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease.
  • 6-Mercaptopurine (6-MP) maintains remission in pediatric Crohn's disease (CD).
  • Azathioprine, a prodrug of 6-MP, is used for maintenance of remission of CD in Europe.
  • We evaluated to what extent azathioprine is used in newly diagnosed pediatric CD patients and whether maintenance of remission differed between patients using azathioprine or not.
  • Active disease was defined as Pediatric Crohn's Disease Activity Index (PCDAI) greater than 10 or systemic corticosteroid use.
  • Remission was defined as PCDAI 10 or less without use of corticosteroids.
  • Median maintenance of first remission in patients who initially used corticosteroids, however, was longer in patients receiving azathioprine compared with nonazathioprine patients (PCDAI, 544 vs. 254 days, P = 0.08; corticosteroid free, 575 vs. 259 days, P < 0.05, respectively).
  • We conclude that, since 2000, azathioprine is being introduced earlier in the treatment of newly diagnosed pediatric CD patients.
  • The use of azathioprine is associated with prolonged maintenance of the first remission.
  • [MeSH-minor] Adolescent. Child. Drug Administration Schedule. Female. Humans. Male. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954801.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] MRK240IY2L / Azathioprine
  •  go-up   go-down


24. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PD, Macedo CR, Lee ML: Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol; 2009 Jul;7(7):465-72
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited.
  • Hyperglycemia has been described as a common event occurring during acute lymphocytic leukemia chemotherapy.
  • Our goal was to compare clinical and laboratory findings between hyperglycemic episodes occurring during childhood acute lymphocytic leukemia induction chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Glucocorticoids / adverse effects. Hyperglycemia / chemically induced. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Amylases / blood. Blood Glucose / metabolism. Body Mass Index. Child. Child, Preschool. Female. Humans. Infant. Male. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701154.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / Glucocorticoids; EC 3.2.1.- / Amylases
  •  go-up   go-down


25. Wynands J, Belbouab R, Candon S, Talbotec C, Mougenot JF, Chatenoud L, Schmitz J, Cézard JP, Goulet O, Hugot JP, Ruemmele FM: 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr; 2008 Mar;46(3):293-8
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
  • AIM: Infliximab (IFX) therapy is highly efficacious for the induction and maintenance of remission in pediatric Crohn disease (CD).
  • Given the increasing safety concerns about the concomitant and prolonged use of IFX and azathioprine in CD, we wanted to address the clinical outcome in pediatric CD patients who responded to IFX medication, once IFX was stopped.
  • PATIENTS AND METHODS: Upon induction therapy with 3 IFX infusions, 36 of 38 patients with CD were in clinical remission at 3 months.
  • In the group receiving maintenance therapy, 11 of 20 patients remained in clinical remission at 12 months of therapy, whereas 8 patients required adjustment of IFX doses or intervals.
  • Among the 11 children who were in clinical remission and receiving maintenance therapy without dose adjustment, 8 experienced relapse within 12 months after IFX maintenance therapy was stopped.
  • CONCLUSIONS: These data indicate that IFX is efficacious in controlling severe pediatric CD; however, to induce and maintain clinical remission, repeated IFX infusions are required, with a need for dose adjustment in a substantial number of patients.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Crohn Disease / drug therapy. Recurrence. Remission Induction / methods

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376247.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; B72HH48FLU / Infliximab
  •  go-up   go-down


26. Hijiya N, Stewart CF, Zhou Y, Campana D, Coustan-Smith E, Rivera GK, Relling MV, Pui CH, Gajjar A: Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer; 2008 May 1;112(9):1983-91
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
  • BACKGROUND: The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse.
  • CONCLUSIONS: A regimen comprising single-agent topotecan given with a standard 3-drug combination was effective in inducing remission in pediatric patients with relapsed ALL and was tolerated well.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318429.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 36401; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / CA 60419; United States / NCI NIH HHS / CA / CA 71907; United States / NCI NIH HHS / CA / CA 78224; United States / NIGMS NIH HHS / GM / GM 61393
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7M7YKX2N15 / Topotecan; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


27. Jacobs JE, Hastings C: Isolated extramedullary relapse in childhood acute lymphocytic leukemia. Curr Hematol Malig Rep; 2010 Oct;5(4):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated extramedullary relapse in childhood acute lymphocytic leukemia.
  • Although the vast majority of children with acute lymphocytic leukemia attain remission with modern therapies, an unacceptably high number will suffer a disease relapse.
  • Both the duration of remission and the site of relapse are important prognostic factors.
  • Finally, the evolution of leukemia therapy is reviewed, bringing into focus the goals and challenges of future therapeutic endeavors.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20717757.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


28. Brochstein JA, Grupp S, Yang H, Pillemer SR, Geba GP: Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease. Pediatr Transplant; 2010 Mar;14(2):233-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.
  • In a phase-1 study, siplizumab, a humanized anti-CD2 monoclonal antibody, was administered (0.012 or 0.04 mg/kg) to 10 pediatric patients with > or = grade-II newly diagnosed, non-steroid-refractory aGvHD after BMT or PBSCT.
  • By study day 12, GvHD grade decreased in 3/5 and 2/5 patients in the 0.012 and 0.04 mg/kg groups, respectively; remission (grade 0) occurred in one patient in each group.
  • While treatment with siplizumab was associated with improvement of GvHD and remission in some pediatric patients, the overall high morbidity, mortality, and occurrence of PTLD is of safety concern, not warranting further development of siplizumab for the treatment of aGvHD in children.
  • [MeSH-minor] Acute Disease. Adolescent. Antibodies, Monoclonal, Humanized. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671093.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / siplizumab
  •  go-up   go-down


29. Ziyab AH, Raza A, Karmaus W, Tongue N, Zhang H, Matthews S, Arshad SH, Roberts G: Trends in eczema in the first 18 years of life: results from the Isle of Wight 1989 birth cohort study. Clin Exp Allergy; 2010 Dec;40(12):1776-84
MedlinePlus Health Information. consumer health - Eczema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Trends in the prevalence of eczema in the course of childhood and adolescence are not clear although often a net remission during childhood is assumed.
  • RESULTS: The period prevalence of eczema from birth to 18 years of age remained relatively constant (11.9-14.2%) with minimal remission.
  • CONCLUSIONS: We found only a minimal reduction in the prevalence of eczema during childhood and adolescence.

  • Genetic Alliance. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21059120.001).
  • [ISSN] 1365-2222
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL082925
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Boyle B, Mackner L, Ross C, Moses J, Kumar S, Crandall W: A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr; 2010 Dec;51(6):714-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease.
  • BACKGROUND AND AIM: Thiopurines are a common, effective means of maintaining remission in pediatric Crohn disease (CD).
  • The primary outcome was defined as steroid-/infliximab-free remission determined by the physician global assessment at 6 and 12 months.
  • At 6 and 12 months, 13 of 27 patients (48.1%) and 9 of 27 patients (33.3%), respectively, were in steroid-/infliximab-free remission.
  • CONCLUSIONS: MTX can be effective as maintenance therapy for patients with pediatric CD previously intolerant of or unresponsive to thiopurines; however, greater than one third of this cohort required escalation to antitumor necrosis factor therapy within 12 months following MTX initiation.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Child. Female. Humans. Infliximab. Leukopenia / etiology. Male. Methyltransferases / therapeutic use. Nausea / chemically induced. Outcome Assessment (Health Care). Patient Compliance. Remission Induction. Retrospective Studies. Transaminases / metabolism

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706154.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; B72HH48FLU / Infliximab; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.6.1.- / Transaminases; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


31. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF: Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):387-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia.
  • BACKGROUND: Children with acute lymphocytic leukemia (ALL) are at high risk for developing hyperglycemia.
  • [MeSH-major] Hyperglycemia / complications. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Blood Glucose / analysis. Child. Child, Preschool. Female. Humans. Male. Prevalence. Remission Induction / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18523991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


32. Huang XL, Chen J, Ma M, Wang PX, Li ZY: [Diagnosis and treatment of Crohn's disease in children: 10 years' clinical experience]. Zhonghua Er Ke Za Zhi; 2007 Apr;45(4):248-51
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To enhance our understanding of pediatric Crohn's disease and improve diagnostic accuracy and therapeutic efficacy by characterizing the clinical picture and reviewing 10 years' clinical experience in diagnosis and treatment.
  • All the other 7 patients were treated with 5-acetylsalicylic acid, antibiotics and nutritional support during the acute phase.
  • Long-term remission was achieved and maintained in 3 children, and in one of them medication could be discontinued and had no signs of disease activity at the end of the follow-up.
  • Appropriate formulation and higher dosage of 5-acetylsalicylic acid [30-50 mg/(kg x d)] may be effective in inducing and maintaining remission in pediatric Crohn's disease.

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706058.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Wang Z, Hu T, Cao LZ, Kang R, Zhao MY, Yu Y, Xu WQ: [Expression of WAVE1 in childhood acute lymphocytic leukemia and in the apoptosis of Jurkat cells induced by adriamycin]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct;10(5):620-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of WAVE1 in childhood acute lymphocytic leukemia and in the apoptosis of Jurkat cells induced by adriamycin].
  • OBJECTIVE: To investigate whether WASP/Verprolin homologous protein 1 (WAVE1) plays a role in the pathogenesis of childhood acute lymphoblastic leukemia (ALL).
  • METHODS: WAVE1 mRNA and protein expression in bone marrow mononuclear cells (BMMCs) was measured by RT-PCR and Western blotting respectively in 4 children with ALL relapse, 15 children with ALL in complete remission (CR) and 40 children with newly diagnosed ALL.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Doxorubicin / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Wiskott-Aldrich Syndrome Protein Family / physiology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947485.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / RNA, Messenger; 0 / WASF1 protein, human; 0 / Wiskott-Aldrich Syndrome Protein Family; 80168379AG / Doxorubicin
  •  go-up   go-down


34. Campbell LK, Scaduto M, Sharp W, Dufton L, Van Slyke D, Whitlock JA, Compas B: A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2007 Jul;49(1):65-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia.
  • BACKGROUND: Impaired neurocognitive functioning is one increasingly recognized long-term consequence of childhood ALL treatment.
  • PROCEDURE: A comprehensive meta-analytic review of the long-term neurocognitive effects of childhood ALL was conducted.
  • Studies were included if they were published in English, reported original quantitative data on the post-treatment neurocognitive functioning of childhood ALL patients in first remission and control groups, and used neurocognitive measures with adequate psychometric properties and published normative data.
  • Neurocognitive assessment plays a critical role in determining what remedial or specialized instruction is needed in childhood ALL survivors and should be included as a standard part of long-term follow-up care.
  • [MeSH-major] Cognition Disorders / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628558.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Luo CY, Li BS, Jiang H, Gu LJ: [Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):446-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia].
  • OBJECTIVE: To determine whether the high level of asparagine synthetase (AS) expression in childhood acute lymphocytic leukemia (ALL) is associated with an inferior prognosis.
  • 82)] was observed in children failed remission, intermediate level [14.28 (3.20-54.47)] in relapsed children and the lowest level [5.08 (0.84-54.92)] in children with continuous complete remission (CCR) (P<0.05).
  • The AS mRNA level [14.93 (2.48-54.47)] in children with poor outcome (un-remission and relapsed) was significantly higher than that in children in CCR (P<0.01).
  • [MeSH-major] Aspartate-Ammonia Ligase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035175.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


36. Ebeid E, Kamel M, Moussa H, Galal U: ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia. J Egypt Natl Canc Inst; 2008 Jun;20(2):121-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
  • Interest in ZAP-70 has grown since it has been shown, through gene expression profiling, that it is expressed in a subset of cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • PURPOSE: The aim of this study was to investigate the expression of ZAP-70 in leukemic blasts of 50 newly diagnosed patients of B-lineage acute lymphoblastic leukemia (ALL), and to assess the correlation between ZAP-70 expression and various prognostic factors and outcome.
  • PATIENTS AND METHODS: This study included 50 pediatric patients with newly diagnosed B-lineage ALL.
  • They were 28 males (56% ) and 22 females (44% ) presented to the Pediatric Oncology Department, National Cancer Institute, Cairo University, during the period from 2005 to 2007.
  • Fifteen patients (30% ) relapsed after achieving complete remission (CR) and 3 patients (6% ) did not achieve CR.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism
  • [MeSH-minor] Adolescent. Age Factors. Antigens, CD / metabolism. B-Lymphocytes / metabolism. Child. Child, Preschool. Female. Humans. Infant. Male. Prognosis. Remission Induction. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029467.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


37. Hou Y, Hu Q, Liu AG, Zhang LQ, Liu SY: [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy]. Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr;8(2):101-4
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy].
  • METHODS: The expression of survivin protein was detected by immunohistochemical assay in bone marrow cells from 62 children with acute leukemia and 40 hospitalized children who did not have leukemia (Control group), and in a human acute T lymphocytic leukemia cell line (Molt-4 cells) treated in vitro with daunorubicin (DNR).
  • RESULTS: Survivin protein was expressed in 41.9% of the 62 children with acute leukemia but in only 5.0% of the Control group (chi(2)=16.66; P < 0.01).
  • The expression rate of survivin was 46.2% in cytoplasm and 53.9% in nucleus in the children with acute leukemia (chi(2)0.3077; P> 0.05).
  • However, the remission rate of patients in whom survivin expression was seen in the nucleus was significantly higher than that in patients in whom survivin was expressed in cytoplasm after chemotherapy.
  • CONCLUSIONS: Survivin may play an important role in the development and prognosis of childhood acute leukemia.
  • The different expression pattern of survivin in the cytoplasm and the nucleus may be associated with therapeutic efficacy and prognosis in acute leukemia.
  • [MeSH-major] Bone Marrow Cells / chemistry. Daunorubicin / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613699.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


38. Eby GA: Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis. Med Hypotheses; 2005;64(6):1124-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis.
  • Low blood levels of zinc are often noted in acute lymphocytic leukemia (ALL), but zinc is not administered as part of any modern chemotherapy program in the treatment of ALL.
  • The result was a bone marrow remission from 95+% blast cells to an observed zero blast cell count in both hips within the first 14 days of treatment which never relapsed.
  • If a nutrient such as zinc could be shown to strengthen the function of chemotherapy and immune function, then it could be hypothesized that the relapse rate would be lessened since the relapse rate is related to both the rate at which a remission is obtained and the thoroughness of the elimination of leukemic blasts.
  • Since treatment with zinc and other identified deficient nutrients, particularly magnesium, did not appear injurious in ALL and they appear to be highly beneficial, controlled clinical studies of zinc (3.18 mg/kg body weight/day) with magnesium (8.0 mg/kg body weight/day) as adjuvants to chemotherapy in the treatment of childhood ALL are suggested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gluconates / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Zinc / physiology
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Bone Marrow / drug effects. Bone Marrow / pathology. Chemotherapy, Adjuvant. Chickenpox Vaccine / immunology. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Dietary Supplements. Drug Synergism. Female. Humans. Immune System / drug effects. Magnesium Deficiency / etiology. Methotrexate / administration & dosage. Models, Biological. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Remission Induction. Survivors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. AMMONIUM GLUCONATE .
  • Hazardous Substances Data Bank. POTASSIUM GLUCONATE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. GLUCONIC ACID .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. MANGANESE GLUCONATE .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823699.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Chickenpox Vaccine; 0 / Gluconates; 5J49Q6B70F / Vincristine; E7WED276I5 / 6-Mercaptopurine; J41CSQ7QDS / Zinc; R4R8J0Q44B / gluconic acid; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


39. Huang Z, Chai YH, Cen JN, He HL, Li J: [Expression of CYP3A5 mRNA in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul;11(7):549-54
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CYP3A5 mRNA in children with acute leukemia].
  • So far the studies on CYP3A5 gene has only been focused on the leukemia cell lines.
  • This study examined the polymorphism of CYP3A5 and tried to find the possible relationship between CYP3A5 gene expression and treatment outcome or prognosis in children with acute leukemia.
  • METHODS: The genotype distribution of CYP3A5-6986A/G gene polymorphism was detected with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 66 children with newly diagnosed acute leukemia (AL) and 22 control individuals.
  • In patients with acute lymphocytic leukaemia (ALL), the complete remission (CR) rate in the group with a low expression of wt-CYP3A5 mRNA was significantly higher than that in the group with a high expression (p<0.05).
  • Dynamic monitoring for wt-CYP3A5 mRNA expression in the bone marrow may be useful in the evaluation of the disease severity in childhood acute leukemia.
  • [MeSH-major] Cytochrome P-450 CYP3A / genetics. Leukemia / enzymology. RNA, Messenger / analysis
  • [MeSH-minor] Acute Disease. Child. Genotype. Humans. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650988.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


40. Kang R, Tang DL, Cao LZ, Yu Y, Zhang GY, Xiao XZ: [High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):329-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell].
  • In the present study, the investigators explored the clinical significance of alteration in the serum levels of HMGB1 in childhood acute lymphocytic leukemia (ALL) and the mechanism of HMGB1-induced tumor necrosis factor (TNF)-alpha secretion in leukemic cells.
  • METHODS: The serum levels of HMGB1 in healthy children and childhood ALL were assayed by Western blotting.
  • RESULTS: The serum levels of HMGB1 were significantly higher in ALL initial treatment group (n = 15, 43.78 +/- 4.62 microg/ml) than those in healthy control group (n = 15, 0.60 +/- 0.48 microg/ml, P < 0.01) and ALL complete remission group (n = 15, 0.89 +/- 0.62 microg/ml, P < 0.01).
  • No significant difference was found between the healthy control group and ALL complete remission group in HMGB1 levels (P > 0.05).
  • CONCLUSIONS: The measurement of serum HMGB1 is helpful to evaluate the prognosis of the childhood ALL.
  • [MeSH-major] HMGB1 Protein / metabolism. Imidazoles / pharmacology. JNK Mitogen-Activated Protein Kinases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. Tumor Necrosis Factor-alpha / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697615.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / HMGB1 Protein; 0 / Imidazoles; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / SB 203580; 0 / Tumor Necrosis Factor-alpha; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


41. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • METHODS: Patients (1376) up to 18 years of age with first relapse of non-B-cell ALL were treated and achieved a 2nd complete remission (CR).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Germany / epidemiology. Humans. Incidence. Infant. Male. Multicenter Studies as Topic. Remission Induction. Risk Factors. Secondary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


42. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • RESULTS: In total, 243 patients with B-precursor and T-cell ALL were treated according to the protocols.
  • There was a significant difference in the remission rate between the NOPHO-92 protocol (99%; n = 144 patients) and the Adult protocol (90%; n = 99 patients; P < .01), and the event-free survival (EFS) was also superior for the NOPHO-92 protocol compared with the Adult protocol (P < .01).
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. van de Nadort C, Houwen RH, Stapelbroek JM: Re: Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr; 2007 Oct;45(4):490
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis.
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Child. Cholagogues and Choleretics / therapeutic use. Humans. Liver Cirrhosis / etiology. Remission Induction. Ursodeoxycholic Acid / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Pediatr Gastroenterol Nutr. 2006 Sep;43(3):353-6 [16954959.001]
  • (PMID = 18030221.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Cholagogues and Choleretics; 0 / Immunosuppressive Agents; 724L30Y2QR / Ursodeoxycholic Acid; MRK240IY2L / Azathioprine
  •  go-up   go-down


44. Newell-Price J: Adrenal gland: Hypertension during remission of childhood Cushing syndrome. Nat Rev Endocrinol; 2009 Nov;5(11):591-2
MedlinePlus Health Information. consumer health - High Blood Pressure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal gland: Hypertension during remission of childhood Cushing syndrome.


45. Sciaudone G, Pellino G, Guadagni I, Selvaggi F: Infliximab avoiding colectomy and maintaining remission in pediatric immunosuppressive-naïve ulcerative colitis achieving remarkable mucosal healing. Panminerva Med; 2010 Mar;52(1):91-2
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infliximab avoiding colectomy and maintaining remission in pediatric immunosuppressive-naïve ulcerative colitis achieving remarkable mucosal healing.






Advertisement